Brief: Denali Therapeutics Expects Enrollment To Be Completed In Late-Stage Trials For MPS II And ALS IN 2024
08/01/2024 17:50
Jan 8 (Reuters) - Denali Therapeutics Inc DNLI.O :
* DENALI THERAPEUTICS INC - IN 2024, WE EXPECT ENROLLMENT TO
BE
COMPLETED IN OUR LATE-STAGE CLINICAL TRIALS FOR MPS II AND ALS
* DENALI THERAPEUTICS INC - CASH, CASH EQUIVALENTS, AND
MARKETABLE
SECURITIES WERE APPROXIMATELY $1.12 BILLION AS OF SEPTEMBER 30,
2023
* DENALI THERAPEUTICS - ANTICIPATES OPERATING EXPENSES IN
2024
WILL BE LESS THAN OR EQUAL TO THOSE IN 2023 BASED ON
PRIORITIZATION OF ITS PORTFOLIO
Source text for Eikon: ID:nGNX54xPTQ
Further company coverage: DNLI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Denali Therapeutics
See all newsDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers